NewsBenzinga据报道，FDA已受理罗氏旗下基因泰克（Genentech）针对葡萄膜炎性黄斑水肿的Vamikibart生物制品许可申请（BLA），预计将于2027年7月作出批准决定；此前III期数据显示，52周时改善持续维持。 据报道，FDA已受理罗氏旗下基因泰克（Genentech）针对葡萄膜炎性黄斑水肿的Vamikibart生物制品许可申请（BLA），预计将于2027年7月作出批准决定；此前III期数据显示，52周时改善持续维持。 Benzinga 2026.10.12 08:05 (GMT+0) Open on Benzinga Other news JP Morgan Maintains Overweight on First Solar, Lowers Price Target to $252 Karooooo Q2 Adj. EPS $0.57, Inline, Sales $100.292M Beat $97.720M Estimate Karooooo Affirms FY2027 GAAP EPS Guidance of $2.35-$2.44 vs $2.41 Est Lear Appoints Jared Fedele CFO, Effective March 1, 2027, Succeeding Jason Cardew JP Morgan Maintains Overweight on Fervo Energy, Lowers Price Target to $27 Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures
Haemonetics Receives FDA Approval For PerQseal Elite Vascular Closure System For Large-Bore Arterial Procedures
